CAP–IASLC–AMP Molecular Testing Guideline
Which molecular markers to test in lung cancer patients being considered for targeted therapy.
Guidance on selecting molecular tests for lung cancer patients considered for targeted therapy.
What it is
A joint guideline from the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC) and the Association for Molecular Pathology (AMP). It defines which molecular markers should be tested in patients with lung cancer to guide selection of targeted (precision) therapies.
Why it matters
Lung adenocarcinoma can carry specific, treatable molecular alterations. Testing the right markers, such as EGFR mutations and ALK / ROS1 rearrangements, helps identify patients who may benefit from targeted therapy rather than standard chemotherapy alone.
Key points
- Guides selection of biomarkers for targeted therapy in lung cancer
- Covers markers such as EGFR mutations and ALK / ROS1 rearrangements
- Addresses appropriate specimen handling and testing methods
- Supports a rational, evidence-based molecular testing pathway
How our reporting uses it
For lung cases referred for molecular testing, our workflow references these recommendations to help ensure the clinically relevant markers are considered.
Keep reading
Related department: Molecular Diagnostics
Refer a case or start a conversation
Tell us what you need, our team will help with sample requirements, turnaround, and reporting.